IDH2 Inhibitor Crystalline Forms for Stable Drug Manufacturing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for stable crystalline forms of IDH2 inhibitors with consistent physical properties for treating advanced hematologic malignancies like AML, MDS, CMML, myeloid sarcoma, multiple myeloma, and lymphoma, which are characterized by the presence of mutant IDH2 alleles, and these forms should be suitable for large-scale manufacturing and formulation.
Innovation Solution
Development of various crystalline forms of IDH2 inhibitors, such as compound 1 and compound 3, with specific polymorphic structures that maintain stability and consistency under varying environmental conditions, ensuring reproducible pharmaceutical quality and effective treatment of these malignancies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If unstable crystalline forms of IDH2 inhibitors are used, then the manufacturing process becomes simpler, but crystal morphology changes during manufacture and storage resulting in quality control problems
Solution Approach 1:
The patent applies parameter changes by transforming the crystalline form of the IDH2 inhibitor through controlled crystallization processes. Specific parameters such as temperature, pH, solvent composition, and cooling rates are optimized to obtain a stable crystalline form with consistent morphology. This stable form maintains its physical properties throughout storage and manufacturing, preventing quality control issues while remaining amenable to standard pharmaceutical manufacturing processes.
2Adaptability or versatility
If polymorphic forms with different physical properties are produced, then the compound can be formulated in various ways, but solubility and dissolution rates become inconsistent affecting bio-availability
Solution Approach 1:
The patent applies local quality by optimizing specific local properties of the crystalline form, particularly solubility and dissolution characteristics. Through controlled crystallization conditions, the patent obtains a crystalline form with uniform molecular arrangement and consistent physical properties. This ensures that the compound exhibits reproducible solubility and dissolution rates across different batches, which is critical for consistent bio-availability and therapeutic effect.
3Reliability
If crystalline forms are stabilized through controlled crystallization, then physical properties become consistent, but the crystallization process becomes more complex
Solution Approach 1:
The patent applies preliminary action by pre-establishing optimized crystallization conditions before actual crystallization occurs. This includes pre-determining optimal temperature profiles, pH levels, solvent systems, and seeding conditions. By preparing and validating these conditions in advance, the patent simplifies the actual crystallization process while ensuring consistent production of the stable crystalline form with reliable physical properties.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline forms of IDH2 inhibitors provide stable and reproducible pharmaceutical compositions that effectively treat advanced hematologic malignancies by inhibiting mutant IDH2 neoactivity, maintaining consistent physical properties and manufacturing suitability.
Implementation Method 1
When a compound crystallizes from a solution or slurry, it may crystallize with different spatial lattice arrangements, a property referred to as 'polymorphism.' Each of the crystal forms is a 'polymorph.' While polymorphs of a given substance have the same chemical composition, they may differ from each other with respect to one or more physical properties, such as solubility and dissociation, true density, melting point, crystal shape, compaction behavior, flow properties, and/or solid state stability.
Data Source
AI summary
Provided are compounds useful for treating of cancer and methods for treating of cancer, comprising administering to a subject in need thereof a compound described therein.